A new company has been set up in the UK to acquire clinical assets that large pharma companies may not be in a position to develop further. The first programmes acquired by Mereo BioPharma Group Ltd are three mid-stage clinical assets from Novartis. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News Clinical Research
